Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Coagulation01:09

Coagulation

8.8K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
8.8K
Coagulation01:06

Coagulation

653
Colloidal solids are solid particles suspended in solution. They are usually negatively charged, attracting a compact primary layer of positively charged ions, which attract more counterions to form an electrical double layer. Electrostatic repulsion between the charged double layers prevents the particles from colliding, stabilizing the colloids. These solids are often undesirable because they can contain toxins that are difficult to remove. Coagulation is a technique that helps aggregate and...
653
Disorders of Hemostasis01:24

Disorders of Hemostasis

1.6K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
1.6K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

1.3K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.3K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

1.7K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.7K
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

126
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
126

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Interdisciplinary recommendations for thrombophilia testing.

Casopis lekaru ceskych·2026
Same author

Sustained Expression of Plasminogen Activator Inhibitor-1 in Patients Recovered from COVID-19 Disease.

Medical principles and practice : international journal of the Kuwait University, Health Science Centre·2025
Same author

Comparative analysis of COVID-19-associated venous thromboembolism outcomes: evolution from 2020 to 2021-2022.

Journal of thrombosis and thrombolysis·2024
Same author

The Prognostic Impact of Renal Function Decline during Hospitalization for Heart Failure.

Kidney & blood pressure research·2023
Same author

Dosing of basic pharmacotherapy and its effect on the prognosis of patients hospitalized for heart failure.

Vnitrni lekarstvi·2023
Same author

Isolated pulmonary embolism - a specific clinical entity?

Vnitrni lekarstvi·2023

Related Experiment Video

Updated: Nov 23, 2025

Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients
04:56

Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients

Published on: August 4, 2023

1.0K

Coagulopathy associated with COVID-19.

Simona Bílková, Jana Hirmerová

    Vnitrni Lekarstvi
    |December 31, 2020
    PubMed
    Summary

    COVID-19 infection presents diverse symptoms, from mild to severe. Severe cases show hypercoagulation and vascular damage, increasing mortality risk due to coagulopathy associated with COVID-19 (CAC).

    Area of Science:

    • Infectious Diseases
    • Hematology
    • Cardiovascular Medicine

    Background:

    • The novel coronavirus (SARS-CoV-2) causes COVID-19, a disease with a wide spectrum of clinical manifestations.
    • While some infections are asymptomatic or mild (e.g., olfactory loss, fatigue), others progress to severe illness.
    • Severe COVID-19 is frequently associated with hypercoagulation, endothelial damage, and thrombotic complications.

    Purpose of the Study:

    • To highlight the significant clinical impact of coagulopathy associated with COVID-19 (CAC).
    • To emphasize how CAC worsens patient prognosis and increases overall mortality.
    • To underscore the need for further research into the treatment of COVID-19, particularly concerning hemostatic dysregulation.

    Main Methods:

    • Review of clinical findings in COVID-19 patients.
    Keywords:
    COVID-19CoagulopathyD-dimersHeparinheparineimmuno-trombosisliver cirrhosis

    More Related Videos

    Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
    04:37

    Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

    Published on: May 23, 2025

    863
    Author Spotlight: Unveiling the Polyfunctionality and Heterogeneity in Immune Responses
    09:43

    Author Spotlight: Unveiling the Polyfunctionality and Heterogeneity in Immune Responses

    Published on: March 8, 2024

    2.1K

    Related Experiment Videos

    Last Updated: Nov 23, 2025

    Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients
    04:56

    Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients

    Published on: August 4, 2023

    1.0K
    Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
    04:37

    Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

    Published on: May 23, 2025

    863
    Author Spotlight: Unveiling the Polyfunctionality and Heterogeneity in Immune Responses
    09:43

    Author Spotlight: Unveiling the Polyfunctionality and Heterogeneity in Immune Responses

    Published on: March 8, 2024

    2.1K
  • Analysis of the relationship between viral infection, endothelial damage, and hypercoagulation.
  • Examination of the impact of coagulopathy on patient outcomes and mortality.

    • Main Results:

    • COVID-19 exhibits diverse clinical presentations, ranging from asymptomatic to severe.
    • Hypercoagulation and vascular endothelial damage are common in severe COVID-19 cases.
    • Coagulopathy significantly correlates with worsened prognosis and increased mortality.

    Conclusions:

    • Coagulopathy associated with COVID-19 (CAC) is a critical factor influencing disease severity and survival.
    • Understanding and managing CAC is crucial for improving patient outcomes.
    • Further research is imperative to develop effective therapeutic strategies for COVID-19, especially for managing its thrombotic and hemostatic complications.